2009
News the public should rely on
DeVita V. News the public should rely on. Nature Reviews Clinical Oncology 2009, 6: 59-59. PMID: 19180108, DOI: 10.1038/ncponc1301.Peer-Reviewed Original Research
2008
Strong inference
DeVita V. Strong inference. Nature Reviews Clinical Oncology 2008, 5: 177-177. PMID: 18376422, DOI: 10.1038/ncponc1094.Peer-Reviewed Original Research
2006
A step in the right direction
DeVita V. A step in the right direction. Nature Reviews Clinical Oncology 2006, 3: 641-641. PMID: 17139311, DOI: 10.1038/ncponc0669.Peer-Reviewed Original Research
1992
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E, Phares J, Jaffe E, Urba W, DeVita V. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. Journal Of Clinical Oncology 1992, 10: 210-8. PMID: 1732422, DOI: 10.1200/jco.1992.10.2.210.Peer-Reviewed Original ResearchConceptsComplete response rateInitial remissionComplete remissionCombination chemotherapyHodgkin's diseaseSalvage therapyOverall survivalPeripheral blood stem cell supportResponse rateChemotherapy-induced complete remissionConventional-dose salvage therapyDate of relapseDurable second remissionsRemission 5 yearsSalvage combination chemotherapyShort initial remissionTreatment-related complicationsDisease-free survivalClinical prognostic factorsStem cell supportDuration of responsePrimary treatment regimenRelapse of patientsNational Cancer InstituteB symptomsThe use of combination chemotherapy in the treatment of early stage Hodgkin's disease.
Longo D, DeVita V. The use of combination chemotherapy in the treatment of early stage Hodgkin's disease. Important Advances In Oncology 1992, 155-65. PMID: 1582671.Peer-Reviewed Original Research